Phytoceuticals: The new ‘physic garden’ for asthma and chronic obstructive pulmonary disease

Expert Review of Respiratory Medicine

Volumn 1, Issue 2, 2007, Pages 227-246

  Grandhi, Sumalatha ^a   Donnelly, Louise E ^a   Rogers, Duncan F ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

butterbur; chocolate; epigallocatechin; flavonoid; petasin; quercetin; red wine; resveratrol; saponin; theobromine

Indexed keywords

EID: 85015608211     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.1.2.227     Document Type: Article

References (197)

1. Hill AW. The history and functions of botanic gardens. Ann. Missouri Bot. Garden 2, 185–240 (1915).
2. Leonard P, Sur S. Asthma: future directions. Med. Clin. North Am. 86, 1131–1156 (2002).
3. World Health Organization. WHO factsheet 206: bronchial asthma. World Health Organization (2000).
4. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59, 469–478 (2004).
5. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349, 1436–1442 (1997).
6. Petty TL. COPD in perspective. Chest 121, S116 –S120 (2002).
7. Culpitt SV, Rogers DF. Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease. Expert Opin. Pharmacother. 1, 1007–1020 (2000).
8. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 161, 381–390 (2000).
9. Willemse BWM, ten Hacken NHT, Rutgers B, Lesman-Leegte IGAT, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur. Respir. J. 26, 835–845 (2005).
10. Kay AB. Allergy and allergic diseases. First of two parts. N. Engl. J. Med. 344, 30–37 (2001).
11. Fahy JV, Corry DB, Boushey HA. Airway inflammation and remodeling in asthma. Curr. Opin. Pulm. Med. 6, 15–20 (2000).
12. Fireman P. Understanding asthma pathophysiology. Allergy Asthma Proc. 24, 79–83 (2003).
13. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST. Airway remodeling in asthma: new insights. J. Allergy Clin. Immunol. 111, 215–225 (2003).
14. Nightingale JA, Rogers DF, Barnes PJ. Effect of inhaled ozone on exhaled nitric oxide, pulmonary function, and induced sputum in normal and asthmatic subjects. Thorax 54, 1061–1069 (1999).
15. Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J. Allergy Clin. Immunol. 112, 819–827 (2003).
16. Ricciardolo FL, Di Stefano A, Sabatini F, Folkerts G. Reactive nitrogen species in the respiratory tract. Eur. J. Pharmacol. 533, 240–252 (2006).
17. Nightingale JA, Maggs R, Cullinan P et al. Airway inflammation after controlled exposure to diesel exhaust particulates. Am. J. Respir. Crit. Care Med. 162, 161–166 (2000).
18. Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs 63, 1973–1998 (2003).
19. 2-adrenoceptor agonists: historical background. Clin. Rev. Allergy Immunol. 31, 107–118 (2006).
20. Broadley KJ. β-adrenoceptor responses of the airways: for better or worse? Eur. J. Pharmacol. 533, 15–27 (2006).
21. McDonald NJ, Bara AI. Anticholinergic therapy for chronic asthma in children over two years of age. Cochrane Database Syst. Rev. CD003535 (2003).
22. 2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane. Database. Syst. Rev. 3, CD001104 (2006).
23. Salpeter SR, Buckley NS. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: β-agonist use compared with anticholinergics and inhaled corticosteroids. Clin. Rev. Allergy Immunol. 31, 219–230 (2006).
24. 2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 65, 1595–1610 (2005).
25. Barr RG, Bourbeau J, Camargo CA, Ram FSF. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 61, 854–862 (2006).
26. Whitehouse MW. Drugs to treat inflammation: a historical introduction. Curr. Med. Chem. 12, 2931–2942 (2005).
27. Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 365, 974–976 (2005).
28. Burge PS. EUROSCOP, ISOLDE and the Copenhagen City Lung Study. Thorax 54, 287–288 (1999).
29. Walters JA, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. CD005374 (2005).
30. Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2, 445–455 (2005).
31. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 363, 731–733 (2004).
32. 2-agonists in asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 1, 200–206 (2004).
33. Akazawa M, Stempel DA. Single-inhaler combination therapy for asthma: a review of cost effectiveness. Pharmacoeconomics 24, 971–988 (2006).
34. Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 60, 1207–1233 (2000).
35. Tal A, Simon G, Vermeulen JH et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr. Pulmonol. 34, 342–350 (2002).
36. Cockcroft DW. Pharmacologic therapy for asthma: overview and historical perspective. J. Clin. Pharmacol. 39, 216–222 (1999).
37. Angsten JM. Use of complementary and alternative medicine in the treatment of asthma. Adolesc. Med. 11, 535–546 (2000).
38. Anon Petasites hybridus. Altern. Med. Rev. 6, 207–209 (2001).
39. Kalin P. [The common butterbur (Petasites hybridus) – portrait of a medicinal herb]. Forsch. Komplementarmed. Klass. Naturheilkd. 10 (Suppl. 1), 41–44 (2003).
40. Lipton RB, Gobel H, Einhaupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 63, 2240–2244 (2004).
41. Thomet OA, Wiesmann UN, Schapowal A, Bizer C, Simon HU. Role of petasin in the potential anti-inflammatory activity of a plant extract of Petasites hybridus. Biochem. Pharmacol. 61, 1041–1047 (2001).
42. Thomet OA, Wiesmann UN, Blaser K, Simon HU. Differential inhibition of inflammatory effector functions by petasin, isopetasin and neopetasin in human eosinophils. Clin. Exp. Allergy 31, 1310–1320 (2001).
43. Ko WC, Lei CB, Lin YL, Chen CF. Relaxant effects of petasins in isolated guinea pig trachea and their structure–activity relationships. Planta Med. 66, 650–652 (2000).
44. Ko WC, Lei CB, Lin YL, Chen CF. Mechanisms of relaxant action of S-petasin and S-isopetasin, sesquiterpenes of Petasites formosanus, in isolated guinea pig trachea. Planta Med. 67, 224–229 (2001).
45. Wang GJ, Liao JF, Hintz KK et al. Calcium-antagonizing activity of S-petasin, a hypotensive sesquiterpene from Petasites formosanus, on inotropic and chronotropic responses in isolated rat atria and cardiac myocytes. Naunyn Schmiedebergs Arch. Pharmacol. 369, 322–329 (2004).
46. 2+ entry blockers on airway constriction induced by muscarinic receptor stimulation. Br. J. Anaesth. 90, 671–675 (2003).
47. Schapowal A. Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis. Br. Med. J. 324, 144–146 (2002).
48. Lee DK, Carstairs IJ, Haggart K, Jackson CM, Currie GP, Lipworth BJ. Butterbur, a herbal remedy, attenuates adenosine monophosphate induced nasal responsiveness in seasonal allergic rhinitis. Clin. Exp. Allergy 33, 882–886 (2003).
49. Gray RD, Haggart K, Lee DK, Cull S, Lipworth BJ. Effects of butterbur treatment in intermittent allergic rhinitis: a placebo-controlled evaluation. Ann. Allergy Asthma Immunol. 93, 56–60 (2004).
50. Kaufeler R, Polasek W, Brattstrom A, Koetter U. Efficacy and safety of butterbur herbal extract Ze 339 in seasonal allergic rhinitis: postmarketing surveillance study. Adv. Ther. 23, 373–384 (2006).
51. Lee DK, Haggart K, Robb FM, Lipworth BJ. Butterbur, a herbal remedy, confers complementary anti-inflammatory activity in asthmatic patients receiving inhaled corticosteroids. Clin. Exp. Allergy 34, 110–114 (2004).
52. Ziolo G, Samochowiec L. Study on clinical properties and mechanisms of action of Petasites in bronchial asthma and chronic obstructive bronchitis. Pharm. Acta Helv. 72, 378–380 (1998).
53. Danesch U, Rittinghausen R. Safety of a patented special butterbur root extract for migraine prevention. Headache 43, 76–78 (2003).
54. Grieve M. A Modern Herbal. (1971).
55. Demirci B, Goppel M, Demirci F, Franz G. HPLC profiling and quantification of active principles in leaves of Hedera helix L. Pharmazie 59, 770–774 (2004).
56. Julien J, Gasquet M, Maillard C, Balansard G, Timon-David P. Extracts of the ivy plant, Hedera helix, and their anthelminthic activity on liver flukes. Planta Med. 51, 205–208 (1985).
57. Elias R, Diaz Lanza AM, Vidal-Ollivier E, Balansard G, Faure R, Babadjamian A. Triterpenoid saponins from the leaves of Hedera helix. J. Natural Products 54, 98–103 (1991).
58. Timon-David P, Julien J, Gasquet M, Balansard G, Bernard P. [Research of antifungal activity from several active principle extracts from climbing-ivy: Hedera helix L (author’s transl)]. Ann. Pharm. Fr. 38, 545–552 (1980).
59. Hostettmann K. Saponins with molluscicidal activity from Hedera helix. Helvetica Chimica Acta 63, 606–609 (1980).
60. Suleyman H, Mshvildadze V, Gepdiremen A, Elias R. Acute and chronic antiinflammatory profile of the ivy plant, Hedera helix, in rats. Phytomedicine 10, 370–374 (2003).
61. Facino RM, Carini M, Stefani R, Aldini G, Saibene L. Anti-elastase and anti-hyaluronidase activities of saponins and sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: factors contributing to their efficacy in the treatment of venous insufficiency. Arch. Pharm. (Weinheim) 328, 720–724 (1995).
62. Trute A, Gross J, Mutschler E, Nahrstedt A. In vitro antispasmodic compounds of the dry extract obtained from Hedera helix. Planta Med. 63, 125–129 (1997).
63. Billington T, Pharmawati M, Gehring CA. Isolation and immunoaffinity purification of biologically active plant natriuretic peptide. Biochem. Biophys. Res. Commun. 235, 722–725 (1997).
64. Mikawa K, Kume H, Takagi K. Effects of atrial natriuretic peptide and 8-brom cyclic guanosine monophosphate on human tracheal smooth muscle. Arzneimittelforschung 48, 914–918 (1998).
65. Hofmann D, Hecker M, Volp A. Efficacy of dry extract of ivy leaves in children with bronchial asthma – a review of randomized controlled trials. Phytomedicine 10, 213–220 (2003).
66. Hecker M, Runkel F, Voelp A. [Treatment of chronic bronchitis with ivy leaf special extract – multicenter post-marketing surveillance study in 1,350 patients]. Forsch. Komplementarmed. Klass. Naturheilkd. 9, 77–84 (2002).
67. Buechi S, Vogelin R, von Eiff MM, Ramos M, Melzer J. Open trial to assess aspects of safety and efficacy of a combined herbal cough syrup with ivy and thyme. Forsch. Komplementarmed. Klass. Naturheilkd. 12, 328–332 (2005).
68. Fazio S, Pouso J, Dolinsky D et al. Tolerance, safety and efficacy of Hedera helix extract in inflammatory bronchial diseases under clinical practice conditions: A prospective, open, multicentre postmarketing study in 9657 patients. Phytomedicine (2006) (Epub ahead of print).
69. Mahran GH, Hilal SH, el Alfy TS. The isolation and characterisation of emetine alkaloid from Hedera helix. Planta Med. 27, 127–132 (1975).
70. Hausen BM, Brohan J, Konig WA, Faasch H, Hahn H, Bruhn G. Allergic and irritant contact dermatitis from falcarinol and didehydrofalcarinol in common ivy (Hedera helix L.). Contact Dermatitis 17, 1–9 (1987).
71. Yesudian PD, Franks A. Contact dermatitis from Hedera helix in a husband and wife. Contact Dermatitis 46, 125–126 (2002).
72. Keen CL. Chocolate: food as medicine/medicine as food. J. Am. Coll. Nutr. 20, S436 –S439 (2001).
73. Lee KW, Kim YJ, Lee HJ, Lee CY. Cocoa has more phenolic phytochemicals and a higher antioxidant capacity than teas and red wine. J. Agric. Food Chem. 51, 7292–7295 (2003).
74. Kris-Etherton PM, Keen CL. Evidence that the antioxidant flavonoids in tea and cocoa are beneficial for cardiovascular health. Curr. Opin. Lipidol. 13, 41–49 (2002).
75. Lotito SB, Actis-Goretta L, Renart ML et al. Influence of oligomer chain length on the antioxidant activity of procyanidins. Biochem. Biophys. Res. Comm. 276, 945–951 (2000).
76. Selmi C, Mao TK, Keen CL, Schmitz HH, Eric GM. The anti-inflammatory properties of cocoa flavanols. J. Cardiovasc. Pharmacol. 47 (Suppl. 2), S163 –S171 (2006).
77. Lotito SB, Fraga CG. Catechins delay lipid oxidation and α-tocopherol and β-carotene depletion following ascorbate depletion in human plasma. Proc. Soc. Exp. Biol. Med. 225, 32–38 (2000).
78. Ono K, Takahashi T, Kamei M et al. Effects of an aqueous extract of cocoa on nitric oxide production of macrophages activated by lipopolysaccharide and interferon-γ. Nutrition 19, 681–685 (2003).
79. Mackenzie GG, Carrasquedo F, Delfino JM, Keen CL, Fraga CG, Oteiza PI. Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-κB activation at multiple steps in Jurkat T cells. FASEB J. 18, 167–169 (2004).
80. Mao T, Van de Water J, Keen CL, Schmitz HH, Gershwin ME. Cocoa procyanidins and human cytokine transcription and secretion. J. Nutr. 130, S2093 –S2209 (2000).
81. Mao TK, van de WJ, Keen CL, Schmitz HH, Gershwin ME. Modulation of TNF-α secretion in peripheral blood mononuclear cells by cocoa flavanols and procyanidins. Dev. Immunol. 9, 135–141 (2002).
82. Arteel GE, Schroeder P, Sies H. Reactions of peroxynitrite with cocoa procyanidin oligomers. J. Nutr. 130, S2100 –S22104 (2000).
83. Usmani OS, Belvisi MG, Patel HJ et al. Theobromine inhibits sensory nerve activation and cough. FASEB J. 19, 231–233 (2004).
84. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 16, 457–499 (1998).
85. Brown MA, Hural J. Functions of IL-4 and control of its expression. Crit. Rev. Immunol. 17, 1–32 (1997).
86. Wang JF, Schramm DD, Holt RR et al. A dose–response effect from chocolate consumption on plasma epicatechin and oxidative damage. J. Nutr. 130, S2115 –S2119 (2000).
87. Rein D, Lotito S, Holt RR, Keen CL, Schmitz HH, Fraga CG. Epicatechin in Human plasma: in vivo determination and effect of chocolate consumption on plasma oxidation status. J. Nutr. 130, S2109 –S2214 (2000).
88. Mumford GK, Benowitz NL, Evans SM et al. Absorption rate of methylxanthines following capsules, cola and chocolate. Eur. J. Clin. Pharmacol. 51, 319–325 (1996).
89. Simons FE, Becker AB, Simons KJ, Gillespie CA. The bronchodilator effect and pharmacokinetics of theobromine in young patients with asthma. J. Allergy Clin. Immunol. 76, 703–707 (1985).
90. Cooper R, Morre DJ, Morre DM. Medicinal benefits of green tea: part I. Review of noncancer health benefits. J. Altern. Complement. Med. 11, 521–528 (2005).
91. Sato T, Miyata G. The nutraceutical benefit, part I: green tea. Nutrition 16, 315–317 (2000).
92. Khokhar S, Venema D, Hollman PC, Dekker M, Jongen W. A RP-HPLC method for the determination of tea catechins. Cancer Lett. 114, 171–172 (1997).
93. Salah N, Miller NJ, Paganga G, Tijburg L, Bolwell GP, Rice-Evans C. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch. Biochem. Biophys. 322, 339–346 (1995).
94. Dufresne CJ, Farnworth ER. A review of latest research findings on the health promotion properties of tea. J. Nutr. Biochem. 12, 404–421 (2001).
95. Lin YL Lin JK. (-)-epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-κB. Mol. Pharmacol. 52, 465–472 (1997).
96. Syed DN, Afaq F, Kweon MH et al. Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-κB activation in normal human bronchial epithelial cells. Oncogene 26, 673–682 (2007).
97. Kim IB, Kim DY, Lee SJ et al. Inhibition of IL-8 production by green tea polyphenols in human nasal fibroblasts and a549 epithelial cells. Biol. Pharm. Bull. 29, 1120–1125 (2006).
98. Chen PC, Wheeler DS, Malhotra V, Odoms K, Denenberg AG, Wong HR. A green tea-derived polyphenol, epigallocatechin-3-gallate, inhibits IκB kinase activation and IL-8 gene expression in respiratory epithelium. Inflammation 26, 233–241 (2002).
99. Wheeler DS, Catravas JD, Odoms K, Denenberg A, Malhotra V, Wong HR. Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1{β}-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. J. Nutr. 134, 1039–1044 (2004).
100. Yokozawa T, Oura H, Nakagawa H, Sakanaka S, Kim M. Effects of a component of green tea on the proliferation of vascular smooth muscle cells. Biosci. Biotechnol. Biochem. 59, 2134–2136 (1995).
101. Hofbauer R, Frass M, Gmeiner B, Handler S, Speiser W, Kapiotis S. The green tea extract epigallocatechin gallate is able to reduce neutrophil transmigration through monolayers of endothelial cells. Wien. Klin. Wochenschr. 111, 278–282 (1999).
102. Alexis AF, Jones VA, Stiller MJ. Potential therapeutic applications of tea in dermatology. Int. J. Dermatol. 38, 735–743 (1999).
103. Rodriguez-Caso C, Rodriguez-Agudo D, Sanchez-Jimenez F, Medina MA. Green tea epigallocatechin-3-gallate is an inhibitor of mammalian histidine decarboxylase. Cell Mol. Life Sci. 60, 1760–1763 (2003).
104. Sartor L, Pezzato E, Garbisa S. (-)epigallocatechin-3-gallate inhibits leukocyte elastase: potential of the phyto-factor in hindering inflammation, emphysema, and invasion. J. Leukoc. Biol. 71, 73–79 (2002).
105. Demeule M, Brossard M, Page M, Gingras D, Beliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochimica Biophysica Acta 1478, 51–60 (2000).
106. Dona M, Dell’Aica I, Calabrese F et al. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J. Immunol. 170, 4335–4341 (2003).
107. Kim SH, Park HJ, Lee CM et al. Epigallocatechin-3-gallate protects toluene diisocyanate-induced airway inflammation in a murine model of asthma. FEBS Lett. 580, 1883–1890 (2006).
108. Bani D, Giannini L, Ciampa A et al. Epigallocatechin-3-gallate reduces allergen-induced asthma-like reaction in sensitized guinea pigs. J. Pharmacol. Exp. Ther. 317, 1002–1011 (2006).
109. Leenen R, Roodenburg AJ, Tijburg LB, Wiseman SA. A single dose of tea with or without milk increases plasma antioxidant activity in humans. Eur. J. Clin. Nutr. 54, 87–92 (2000).
110. Yang F, de Villiers WJ, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. J. Nutr. 128, 2334–2340 (1998).
111. Shirai T, Reshad K, Yoshitomi A, Chida K, Nakamura H, Taniguchi M. Green tea-induced asthma: relationship between immunological reactivity, specific and non-specific bronchial responsiveness. Clin. Exp. Allergy 33, 1252–1255 (2003).
112. Shirai T, Sato A, Chida K et al. Epigallocatechin gallate-induced histamine release in patients with green tea-induced asthma. Ann. Allergy Asthma Immunol. 79, 65–69 (1997).
113. Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am. J. Clin. Nutr. 81, S243 –S255 (2005).
114. Hakkinen SH, Karenlampi SO, Heinonen IM, Mykkanen HM, Torronen AR. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J. Agric. Food Chem. 47, 2274–2279 (1999).
115. Boyer J, Liu RH. Apple phytochemicals and their health benefits. Nutr. J. 3, 5 (2004).
116. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 81, S230 –S242 (2005).
117. Formica JV, Regelson W. Review of the biology of quercetin and related bioflavonoids. Food Chem. Toxicol. 33, 1061–1080 (1995).
118. Chaabi M, Freund-Michel V, Frossard N, Randriantsoa A, Andriantsitohaina R, Lobstein A. Anti-proliferative effect of Euphorbia stenoclada in human airway smooth muscle cells in culture. J. Ethnopharmacol. 109, 134–139 (2007).
119. Paliyath G, Poovaiah BW. Identification of naturally occurring calmodulin inhibitors in plants and their effects on calcium- and calmodulin-promoted protein phosphorylation. Plant Cell Physiol. 26, 201–209 (1985).
120. Nishino H, Naitoh E, Iwashima A, Umezawa K. Quercetin interacts with calmodulin, a calcium regulatory protein. Experientia 40, 184–185 (1984).
121. Nair MPN, Kandaswami C, Mahajan S et al. The flavonoid, quercetin, differentially regulates Th-1 (IFN[γ]) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. Biochim. Biophys. Acta 1593, 29–36 (2002).
122. Kobuchi H, Roy S, Sen CK, Nguyen HG, Packer L. Quercetin inhibits inducible ICAM-1 expression in human endothelial cells through the JNK pathway. Am. J. Physiol. Cell. Physiol. 277, C403 –C411 (1999).
123. Donnelly LE, Newton R, Kennedy GE et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L774 –L783 (2004).
124. Kim HP, Mani I, Iversen L, Ziboh VA. Effects of naturally-occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs. Prostaglandins Leukot. Essent. Fatty Acids 58, 17–24 (1998).
125. Banerjee T, van der Vliet A, Ziboh VA. Downregulation of COX-2 and iNOS by amentoflavone and quercetin in A549 human lung adenocarcinoma cell line. Prostaglandins Leukot. Essent. Fatty Acids 66, 485–492 (2002).
126. Okamoto K, Kim JS, Rubin BK. Secretory phospholipases A2 stimulate mucus secretion, induce airway inflammation, and produce secretory hyperresponsiveness to neutrophil elastase in ferret trachea. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, L62 –L67 (2007).
127. Zaslaver M, Offer S, Kerem Z et al. Natural compounds derived from foods modulate nitric oxide production and oxidative status in epithelial lung cells. J. Agric. Food Chem. 53, 9934–9939 (2005).
128. Shen SC, Lee WR, Lin HY et al. In vitro and in vivo inhibitory activities of rutin, wogonin, and quercetin on lipopolysaccharide-induced nitric oxide and prostaglandin E(2) production. Eur. J. Pharmacol. 446, 187–194 (2002).
129. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95–105 (2000).
130. Agullo G, Gamet-Payrastre L, Manenti S et al. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem. Pharmacol. 53, 1649–1657 (1997).
131. Huang Y-T, Hwang J-J, Lee P-P et al. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br. J. Pharmacol. 128, 999–1010 (1999).
132. Nanua S, Zick SM, Andrade JE et al. Quercetin blocks airway epithelial cell chemokine expression. Am. J. Respir. Cell Mol. Biol. 35, 602–610 (2006).
133. Ko WC, Shih CM, Chen MC et al. Suppressive effects of 3-O-methylquercetin on ovalbumin-induced airway hyperresponsiveness. Planta Med. 70, 1123–1127 (2004).
134. Raju TAN, Lakshmi ANV, Anand T, Rao LV, Sharma G. Protective effects of quercetin during influenza virus-induced oxidative stress. Asia Pacific J. Clin. Nutr. 9, 314–317 (2000).
135. Kumar P, Sharma S, Khanna M, Raj HG. Effect of quercetin on lipid peroxidation and changes in lung morphology in experimental influenza virus infection. Int. J. Exp. Pathol. 84, 127–133 (2003).
136. Selloum L, Reichl S, Muller M, Sebihi L, Arnhold J. Effects of flavonols on the generation of superoxide anion radicals by xanthine oxidase and stimulated neutrophils. Arch. Biochem. Biophys. 395, 49–56 (2001).
137. Erlund I, Kosonen T, Alfthan G et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur. J. Clin. Pharmacol. 56, 545–553 (2000).
138. Knekt P, Kumpulainen J, Jarvinen R et al. Flavonoid intake and risk of chronic diseases. Am. J. Clin. Nutr. 76, 560–568 (2002).
139. Woods RK, Walters EH, Raven JM et al. Food and nutrient intakes and asthma risk in young adults. Am. J. Clin. Nutr. 78, 414–421 (2003).
140. Shaheen SO, Sterne JAC, Thompson RL, Songhurst CE, Margetts BM, Burney PG. Dietary antioxidants and asthma in adults. population-based case–control study. Am. J. Respir. Crit. Care Med. 164, 1823–1828 (2001).
141. Butland BK, Fehily AM, Elwood PC. Diet, lung function, and lung function decline in a cohort of 2512 middle aged men. Thorax 55, 102–108 (2000).
142. Okoko BJ, Burney PG, Newson RB, Potts JF, Shaheen SO. Childhood asthma and fruit consumption. Eur. Respir. J. 29, 1161–1168 (2007).
143. Garcia V, Arts ICW, Sterne JAC, Thompson RL, Shaheen SO. Dietary intake of flavonoids and asthma in adults. Eur. Respir. J. 26, 449–452 (2005).
144. van der Sluis AA, Dekker M, de Jager A, Jongen WM. Activity and concentration of polyphenolic antioxidants in apple: effect of cultivar, harvest year, and storage conditions. J. Agric. Food Chem. 49, 3606–3613 (2001).
145. Eberhardt MV, Lee CY, Liu RH. Antioxidant activity of fresh apples. Nature 405, 903–904 (2000).
146. Watson L, Margetts B, Howarth P, Dorward M, Thompson R, Little P. The association between diet and chronic obstructive pulmonary disease in subjects selected from general practice. Eur. Respir. J. 20, 313–318 (2002).
147. Tabak C, Arts IC, Smit HA, Heederik D, Kromhout D. Chronic obstructive pulmonary disease and intake of catechins, flavonols, and flavones. The MORGEN Study. Am. J. Respir. Crit. Care Med. 164, 61–64 (2001).
148. Walda IC, Tabak C, Smit HA et al. Diet and 20-year chronic obstructive pulmonary disease mortality in middle-aged men from three European countries. Eur. J. Clin. Nutr. 56, 638–643 (2002).
149. Okamoto T. Safety of quercetin for clinical application (review). Int. J. Mol. Med. 16, 275–278 (2005).
150. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? and gone? Clin. Biochem. 30, 91–113 (1997).
151. Su HY, Cherng SH, Chen CC, Lee H. Emodin inhibits the mutagenicity and DNA adducts induced by 1-nitropyrene. Mutat. Res. 329, 205–212 (1995).
152. Vastano BC, Chen Y, Zhu N, Ho CT, Zhou Z, Rosen RT. Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum. J. Agric. Food Chem. 48, 253–256 (2000).
153. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5, 493–506 (2006).
154. Goldberg DM, Tsang E, Karumanchiri A, Diamandis E, Soleas G, Ng E. Method to assay the concentrations of phenolic constituents of biological interest in wines. Anal. Chem. 68, 1688–1694 (1996).
155. Renaud S, Gueguen R. The French paradox and wine drinking. Novartis Found. Symp. 216, 208–217 (1998).
156. Belleville J. The French paradox: possible involvement of ethanol in the protective effect against cardiovascular diseases. Nutrition 18, 173–177 (2002).
157. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339, 1523–1526 (1992).
158. Burr ML. Explaining the French paradox. JR Soc. Health 115, 217–219 (1995).
159. Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am. J. Eno. Vitic. 43, 49–52 (1992).
160. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J. 17, 1975–1985 (2003).
161. Sun AY, Simonyi A, Sun GY. The “French Paradox” and beyond: neuroprotective effects of polyphenols. Free Radic. Biol. Med. 32, 314–318 (2002).
162. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κ B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164, 6509–6519 (2000).
163. Birrell MA, McCluskie K, Wong S, Donnelly LE, Barnes PJ, Belvisi MG. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-κB-independent mechanism. FASEB J. 19, 840–841 (2005).
164. Christie PE, Henderson WR Jr. Lipid inflammatory mediators: leukotrienes, prostaglandins, platelet-activating factor. Clin. Allergy Immunol. 16, 233–254 (2002).
165. Bittleman DB, Casale TB. 5-hydroxyeicosatetraenoic acid (HETE)-induced neutrophil transcellular migration is dependent upon enantiomeric structure. Am. J. Respir. Cell. Mol. Biol. 12, 260–267 (1995).
166. Schwenk U, Schroder JM. 5-oxo-eicosanoids are potent eosinophil chemotactic factors. J. Biol. Chem. 270, 15029–15036 (1995).
167. Peters SP, Siegel MI, Kagey-Sobotka A, Lichtenstein LM. lipoxygenase products modulate histamine release in human basophils. Nature 292, 455–457 (1981).
168. Szewczuk LM, Forti L, Stivala LA, Penning TM. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J. Biol. Chem. 279, 22727–22737 (2004).
169. Bertelli AA, Baccalini R, Battaglia E, Falchi M, Ferrero ME. Resveratrol inhibits TNF α-induced endothelial cell activation. Therapie 56, 613–616 (2001).
170. Tao HY, Wu CF, Zhou Y et al. The grape component resveratrol interferes with the function of chemoattractant receptors on phagocytic leukocytes. Cell Mol. Immunol. 1, 50–56 (2004).
171. Rotondo S, Rajtar G, Manarini S et al. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br. J. Pharmacol. 123, 1691–1699 (1998).
172. Culpitt SV, Rogers DF, Fenwick PS et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 58, 942–946 (2003).
173. Falchetti R, Fuggetta MP, Lanzilli G, Tricarico M, Ravagnan G. Effects of resveratrol on human immune cell function. Life Sci. 70, 81–96 (2001).
174. Boscolo P, Signore AD, Sabbioni E et al. Effects of resveratrol on lymphocyte proliferation and cytokine release. Ann. Clin. Lab. Sci. 33, 226–231 (2003).
175. Hsieh TC, Halicka D, Lu X et al. Effects of resveratrol on the G0–G1 transition and cell cycle progression of mitogenically stimulated human lymphocytes. Biochem. Biophys. Res. Comm. 297, 1311–1317 (2002).
176. Leonard SS, Xia C, Jiang BH et al. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Comm. 309, 1017–1026 (2003).
177. Taha R, Olivenstein R, Utsumi T et al. Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 161, 636–640 (2000).
178. Culpitt SV, Rogers DF, Shah P et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 167, 24–31 (2003).
179. Schunemann HJ, Grant BJ, Freudenheim JL et al. Beverage specific alcohol intake in a population-based study: evidence for a positive association between pulmonary function and wine intake. BMC Pulm. Med. 2, 3 (2002).
180. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but vey low bioavaliability of oral resveratrol in humans. Drug Metab. Dispos. 32, 1377–1382 (2004).
181. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 49, 472–481 (2005).
182. Vitaglione P, Sforza S, Galaverna G et al. Bioavailability of trans-resveratrol from red wine in humans. Mol. Nutr. Food Res. 49, 495–504 (2005).
183. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 36, 79–87 (2003).
184. Juan ME, Vinardell MP, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr. 132, 257–260 (2002).
185. Dahl R, Henriksen JM, Harving H. Red wine asthma: a controlled challenge study. J. Allergy Clin. Immunol. 78, 1126–1129 (1986).
186. Vally H, Carr A, El-Saleh J, Thompson P. Wine-induced asthma: a placebo-controlled assessment of its pathogenesis. J. Allergy Clin. Immunol. 103, 41–46 (1999).
187. Wantke F, Hemmer W, Haglmuller T, Gotz M, Jarisch R. Histamine in wine. Bronchoconstriction after a double-blind placebo-controlled red wine provocation test. Int. Arch. Allergy Immunol. 110, 397–400 (1996).
188. de Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 30, 857–866 (2000).
189. de Santi C, Pietrabissa A, Mosca F, Pacifici GM. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 30, 1047–1054 (2000).
190. Yu C, Shin YG, Chow A et al. Human, rat, and mouse metabolism of resveratrol. Pharm. Res. 19, 1907–1914 (2002).
191. Perez-Arellano JL, Barrios MN, Martin T, Sanchez ML, Jimenez A, Gonzalez-Buitrago JM. Hydrolytic enzyme of the alveolar macrophage in diffuse pulmonary interstitial disease. Respir. Med. 90, 159–166 (1996).
192. Murr C, Schroecksnadel K, Winkler C, Ledochowski M, Fuchs D. Antioxidants may increase the probability of developing allergic diseases and asthma. Med. Hypotheses 64, 973–977 (2005).
193. Ahn KS, Kim JH, Oh SR, Ryu SY, Lee HK. Inhibitory activity of stilbenes from medicinal plants on the expression of cell adhesion molecules on THP1 cells. Planta Med. 66, 641–644 (2000).
194. Matsuda H, Kageura T, Morikawa T, Toguchida I, Harima S, Yoshikawa M. Effects of stilbene constituents from rhubarb on nitric oxide production in lipopolysaccharide-activated macrophages. Bioorg. Med. Chem. Lett. 10, 323–327 (2000).
195. Wieder T, Prokop A, Bagci B et al. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia 15, 1735–1742 (2001).
196. Global Initiative for Asthma. Global strategy for asthma management and prevention www.ginasthma.org
197. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease www.goldcopd.org